High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris
Authors:
Preprint
Abstract
Background Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Herein, we assessed the serological response against the SARS-CoV-2 virus in a large population working in one institution of the Paris conurbation. We set up two high-throughput and sensitive methods to assess SARS CoV-2 Nucleoprotein and Spike protein-specific IgG response along with a pseudo-neutralization assay in sera. We studied 1847 participants who also answered a web-based survey on clinical symptoms. Methods and Results In May-July 2020, 11% (95% CI: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S protein and 9.5% (CI:8.2-11.0) were pseudo-neutralizer. The prevalence of immunization was 11.6% (CI:10.2-13.2) considering positivity in at least one assays. In 5% (CI:3.9-7.1) of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia and ageusia occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative suggesting that the true prevalence of infection may reach 16.6%. In sera obtained 4-8 weeks after the first sampling anti-N and anti-S IgG titers and pseudo-neutralization activity declined by 31%, 17% and 53%, respectively with half-life of 35, 87 and 28 days, respectively. Conclusions The population studied being not particularly exposed to SARS-CoV-2 infection is representative of active workers in the Paris conurbation, suggesting that the current epidemiological models may underestimate the true prevalence of infection. The short lifespan of the serological systemic responses hinders retrospective assessment of the epidemic extent.Keywords
All Related Versions
- Published version: European Journal of Immunology, 51 (1), 180.
This publication has 29 references indexed in Scilit:
- A highly sensitive bioluminescent method for measuring allergen‐specific IgE in microliter samplesAllergy, 2020
- Clinical and virological data of the first cases of COVID-19 in Europe: a case seriesThe Lancet Infectious Diseases, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of diseasemedRxiv, 2020
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Bioluminescence Profiling of NanoKAZ/NanoLuc Luciferase Using a Chemical Library of Coelenterazine AnaloguesChemistry – A European Journal, 2019
- Gram-scale synthesis of luciferins derived from coelenterazine and original insights into their bioluminescence propertiesOrganic & Biomolecular Chemistry, 2019